The Scripps Research Institute

Dario C Altieri

George B Thornton

Lucia R Languino

Edward F Plow

Thomas S Edgington

The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.

Methods for inhibiting endothelial cell and fibrinogen mediated inflammation using fibrinogen specific antibodies

Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation

Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1

A new class of cellular receptors extensively homologous but not identical to coagulation factors V and VIII is identified. The DNA and amino acid residue sequences of the receptor are also described. The invention also discloses methods, sequences and vectors useful in the purification and synthesis of cellular receptors of the present invention, which receptors are identified herein as Effector Cell Protease Receptor-1 (EPR-1). Antibody compositions capable of immunoreacting with the receptor or with polypeptides containing the identified amino acid residue sequences and related therapeutic and diagnostic protocols are also described, as are polypeptides, compositions and methods relating to the inhibition of T lymphocyte proliferation using the antibodies disclosed herein. The present invention also discloses polypeptides, antibodies and compositions capable of stimulating or co-stimulating lymphocyte proliferation.

EPR-1 proteins, polypeptides, and nucleic acid molecules encoding same

Method of inhibiting fibrinogen binding to endothelial cells with

Fibrinogen .gamma. chain polypeptide and compositions thereof

The present invention contemplates therapeutic compositions containing a D.sub.30 homolog capable of binding to the Mac-1 receptor D.sub.30 binding site and inhibiting fibrinogen binding to the Mac-1 receptor via the D.sub.30 binding site, Methods of inhibiting Mac-1 receptor binding to any Mac-1 ligand and methods of inhibiting Mac-1 receptor mediated inflammation within a patient by administering a D.sub.30 homolog are also contemplated,

Inhibition of Mac-1 receptor binding to fibrinogen using D.sub.30

Growing community of inventors

La Jolla, CA, United States of America

Dario C Altieri